Zostavax Vaccine

Administered as a single subcutaneous injection, Zostavax is contraindicated in individuals with a history of severe allergic reaction to any component of the vaccine, immunocompromised patients, and pregnant women due to the live attenuated nature of the virus. Common adverse reactions include injection site erythema, pain, swelling, and mild systemic symptoms such as headache and fatigue.

The vaccine has demonstrated efficacy in reducing the incidence and severity of shingles and associated complications. Prior to administration, patients should be evaluated for immunocompetence and history of varicella infection or vaccination. Zostavax should be stored frozen and protected from light to maintain potency. It is essential to adhere to recommended immunization schedules and consult healthcare professionals for appropriate patient selection and monitoring post-vaccination.